nach oben

Erschienen in:

01.01.2016 | Original Article

Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

verfasst von: Elena Mazza, Alba Brandes, Silvia Zanon, Marika Eoli, Giuseppe Lombardi, Marina Faedi, Enrico Franceschi, Michele Reni

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Hydroxyurea (HU) is among the most widely used salvage therapies in progressive meningiomas. Platelet-derived growth factor receptors are expressed in virtually all meningiomas. Imatinib sensitizes transformed cells to the cytotoxic effects of chemotherapeutic agents that interfere with DNA metabolism. The combination of HU with imatinib yielded intriguing results in recurrent malignant glioma. The current trial addressed the activity of this association against meningioma.

Methods

Patients with recurrent or progressive WHO grade I–III meningioma, without therapeutic indication for surgery, radiotherapy, or stereotactic radiosurgery, aged 18–75 years, ECOG performance status 0–2, and not on enzyme-inducing anti-epileptic drugs were randomized to receive HU 500 mg BID ± imatinib 400 mg QD until progression, unacceptable toxicity, or patient’s refusal. The primary endpoint was progression-free survival rate at 9 months (PFS-9).

Results

Between September 2009 and February 2012, 15 patients were randomized to receive HU + imatinib (N = 7; Arm A) or HU alone (N = 8; Arm B). Afterward the trial was prematurely closed due to slow enrollment rate. PFS-9 (A/B) was 0/75 %, and median PFS was 4/19.5 months. Median and 2-year overall survival (A/B) rates were: 6/27.5 months; 28.5/75 %, respectively. Main G3-4 toxicities were: G3 neutropenia in 1/0, G4 headache in 1/1, and G3 vomiting in 1/0.

Conclusion

The conduction of a study in recurrent or progressive meningioma remains a challenge. Given the limited number of patients enrolled, no firm conclusions can be drawn about the combination of imatinib and HU. The optimal systemic therapy for meningioma failing surgery and radiation has yet to be identified.

Saraf S, McCarthy BJ, Villano JL (2011) Update on meningiomas. The Oncologist 16:1604–1613 (NCCN CNS v. 2/2014) PubMedPubMedCentralCrossRef

Simpson D (1957) The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 20:22–39PubMedPubMedCentralCrossRef

Kaley T, Barani I, Chamberlain M et al (2014) Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro-Oncology 16:829–840PubMedPubMedCentralCrossRef

Schrell UM, Rittig MG, Anders M et al (1997) Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg 86(5):845–852PubMedCrossRef

Schrell UM, Rittig MG, Anders M et al (1997) Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg 86:840–844PubMedCrossRef

Newton HB, Slivka MA, Stevens C (2000) Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol 49:165–170PubMedCrossRef

Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE (2002) Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg 97:341–346PubMedCrossRef

Rosenthal MA, Ashley DL, Cher L (2002) Treatment of high risk or recurrent meningiomas with hydroxyurea. J Clin Neurosci 9:156–158PubMedCrossRef

Paus S, Klockgether T, Urbach H, Schlegel U (2003) Meningioma of the optic nerve sheath: treatment with hydroxyurea. J Neurol Neurosurg Psychiatry 74:1348–1350PubMedPubMedCentralCrossRef

10.

Loven D, Hardoff R, Sever ZB et al (2004) Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol 67:221–226PubMedCrossRef

11.

Hahn BM, Schrell UM, Sauer R, Fahlbusch R, Ganslandt O, Grabenbauer GG (2005) Prolonged oral hydroxyurea and concurrent 3D-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. J Neurooncol 74:157–165PubMedCrossRef

12.

Wen PY, Yung WK, Lamborn KR et al (2009) Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol 11:853–860PubMedPubMedCentralCrossRef

13.

Swinnen, LJ, Rankin C, Rushing EJ, Laura HF, Damek DM, Barger GR (2009) Phase II study of hydroxyurea for unresectable meningioma (Southwest Oncology Group S9811). In: Journal of Clinical Oncology, ASCO annual meeting proceedings (Post-Meeting Edition), vol 27, No 15S (May 20 Supplement):2063

14.

Chamberlain MC, Johnston SK (2011) Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series. J Neurooncol 104:765–771PubMedCrossRef

15.

Chamberlain MC (2012) Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. J Neurooncol 107:315–321PubMedCrossRef

16.

Holdhoff M, Kreuzer KA, Appett C et al (2005) Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol Dis 34:181–185PubMedCrossRef

17.

O’Reilly T, Wartmann M, Maira SM et al (2004) Patupilone (epothilone B, EPO906) and imatinib (STI571, Imatinib) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma. Cancer Chemother Pharmacol 55:307–317PubMedCrossRef

18.

Katayama R, Huelsmeyer MK, Marr AK et al (2004) Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma. Cancer Chemother Pharmacol 54:25–33PubMedCrossRef

19.

Aloyz R, Grzywacz K, Xu ZY et al (2004) Imatinib sensitizes CLL lymphocytes to chlorambucil. Leukemia 18:409–414PubMedCrossRef

20.

Kano Y, Akutsu M, Tsunoda S et al (2001) In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97:1999–2007PubMedCrossRef

21.

Dogruel M, Gibbs JE, Thomas SA (2003) Hydroxyurea transport across the blood–brain and blood–cerebrospinal fluid barriers of the guinea-pig. J Neurochem 87:76–84PubMedCrossRef

22.

Reardon DA et al (2012) Phase II study of Gleveec^® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neuroncol 106(2):409–415CrossRef

23.

Chamberlain MC, Blumenthal DT (2004) Intracranial meningiomas: diagnosis and treatment. Expert Rev Neurother 4(4):641–648PubMedCrossRef

24.

Kyritsis AP (1996) Chemotherapy for meningiomas. J Neurooncol 29(3):269–272PubMedCrossRef

25.

Chamberlain MC, Tsao-Wei DD, Groshen S (2004) Temozolomide for treatment-resistant recurrent meningioma. Neurology 62(7):1210–1212PubMedCrossRef

26.

Chamberlain MC, Tsao-Wei DD, Groshen S (2006) Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol 78(3):271–276PubMedCrossRef

27.

Newton HB, Scott SR, Volpi C (2004) Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br J Neurosurg 18(5):495–499PubMedCrossRef

28.

Ragel BT, Jensen RL (2010) Aberrant signaling pathways in meningiomas. J Neurooncol 99(3):315–324PubMedCrossRef

29.

Choy W, Kim W, Nagasawa D et al (2011) The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. Neurosurg Focus 30(5):E6PubMed

30.

Johnson MD, O’Connell M, Pilcher W (2011) Lopinavir inhibits meningioma cell proliferation by Akt independent mechanism. J Neurooncol 101(3):441–448PubMedCrossRef

31.

Norden AD, Raizer JJ, Abrey LE et al (2010) Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol 96(2):211–217PubMedPubMedCentralCrossRef

32.

Nayak L, Iwamoto FM, Rudnick JD et al (2012) Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol 109(1):187–193PubMedCrossRef

33.

Lou E, Sumrall AL, Turner S et al (2012) Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol 109(1):63–70PubMedPubMedCentralCrossRef

34.

Raizer JJ, Grimm SA, Rademaker A et al (2014) A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas. J Neurooncol 117(1):93–101PubMedCrossRef

35.

Kaley TJ, Wen P, Schiff D et al (2015) Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol 17(1):116–121PubMedPubMedCentralCrossRef

36.

Preusser M, Spiegl-Kreinecker S, Lötsch D et al (2012) Trabectedin has promising antineoplastic activity in high-grade meningioma. Cancer 118(20):5038–5049PubMedCrossRef

Titel: Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
verfasst von: Elena Mazza
Alba Brandes
Silvia Zanon
Marika Eoli
Giuseppe Lombardi
Marina Faedi
Enrico Franceschi
Michele Reni
Publikationsdatum: 01.01.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 1/2016
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-015-2927-0

Springer Medizin

Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)